Connect with us

Technology

More Than 75 Emerging Biotechs Use Veeva Basics Across Clinical, Regulatory, and Quality

Published

on

Delivers pre-configured, pre-validated software that can scale with the needs of fast-growing companies

BARCELONA, Spain, May 20, 2025 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Veeva Basics is being used by more than 75 biotechs to gain efficiency and reduce costs across clinical, regulatory, and quality. With standardized applications, biotechs are going live with industry-leading software in weeks and gaining a system that can scale as they expand their business. The rapid adoption of Veeva Basics signals a shift from disparate entry-level tools toward complete, best-of-breed solutions that can support biotechs today and as they grow.

Designed specifically for fast-growing companies, Veeva Basics provides pre-configured and pre-validated solutions. This enables fast deployment and adoption regardless of company size. With clinical, regulatory, and quality solutions available, Veeva is adding two new applications for biotechs:

Veeva CTMS Basics for clinical trial management, including milestones, monitoring, enrollment, issue resolution, and site communications.Veeva Submissions Publishing Basics for building, publishing, and transmitting regulatory submissions in a single system.

“More biotechs are adopting Veeva Basics in North America and Europe, driving savings in time, cost, and effort,” said Steve Harper, general manager of Veeva Basics. “Our approach to deliver pre-configured and pre-validated solutions that can go live quickly is gaining momentum, and we’re adding new clinical and regulatory solutions to meet the needs of high-growth companies. With complete cloud applications, biotechs can ensure they are always current and benefit from the latest features.”

Veeva CTMS Basics and Submissions Publishing Basics are available today in North America and Europe. Built on the proven Vault Platform, Veeva Basics applications allow customers to scale their technology infrastructure as they grow. For more on Veeva Basics, visit veeva.com/VeevaBasics.

What biotechs are saying about Veeva Basics:

“I believe Veeva Basics is a game changer, giving smaller biotech companies access to the same modern and connected applications that are typically only available to larger organizations,” said Ian Hodgson, Ph.D., chief operating officer at Corbus Pharmaceuticals, Inc. “As our company continues to grow, I am confident that Veeva’s platform can scale with us and help ensure we remain up to date as regulatory requirements evolve.”

“As we expand our studies to a larger scale, Veeva eTMF Basics gives us more control of our data and process to ensure inspection readiness,” said Joe Thornton, associate director, clinical operations at Scancell. “Having an industry-leading solution with pre-configured best practices as our foundation for trials will help drive speed and innovation as we continue to develop novel immunotherapies.”

“The global support and training provided with Veeva Basics helps us gain maximum value from Veeva’s industry solution,” said Rebecca Deng, Ph.D., associate director, regulatory affairs and QA systems at Terns Pharmaceuticals. “With a simple path to go live and validation, Veeva Basics has delivered significant time and resource savings.”

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

 

View original content:https://www.prnewswire.co.uk/news-releases/more-than-75-emerging-biotechs-use-veeva-basics-across-clinical-regulatory-and-quality-302460181.html

Continue Reading

Technology

Allooloo Tops 100M Capital Markets AI Agent Traffic a Month

Published

on

By

Agentic datasets on every listed company in 34 countries: sourced, dated and signed.

VANCOUVER, BC and LONDON, Nov. 20, 2026 /PRNewswire/ — Allooloo Technologies Corp. (Allooloo), maker of agentic datasets for capital markets artificial intelligence (AI) agents, today reported 100M AI agent traffic a month. That is 39 calls a second, 3.4 million a day, across getissuer.ai and Issuerwire.ai, running on 24 Microsoft Azure hyperscale locations globally with always-on Amazon Web Services (AWS) redundancy.

The Data Readiness Gap

Investment banks are not short of AI models. They are short of data an AI agent can use. In a 2026 Teradata study, 77% of technology leaders said 20% or less of their enterprise data is ready for AI agents. Banks are closing that gap on the data they hold, with one governed way in and the source, the date and the owner on every record.

The data a bank does not hold is the other half. An AI agent working on a security needs the issuer, its disclosures and whether it may be ordered, in every market the bank trades. Allooloo delivers that half agent-ready: 41.9K listed companies in 34 countries, a source and a date on every field, and a signed receipt for every read, over Model Context Protocol (MCP).

Two Products

Know Your Product (KYP) is the duty to know a security before it is recommended or sold. Allooloo KYP, at getissuer.ai, answers it for the AI agent: who the issuer is, whether it may be ordered, and who it is for. It covers 41.9K listed companies on 79 exchanges in 34 countries.

Issuerwire.ai is the dated disclosure wire: 3.1 million dated disclosures across 34 countries, each with its source.

Who it matters to:

Investment bank or dealer: its AI agents can show where each fact came from.The issuer: every AI agent reads the same answer about it.Compliance: a signed receipt for every cleared read.

A Signed Receipt for Every Read

Every cleared read on Allooloo leaves a signed receipt, the Record of Cleared Orders (RCO): what was read, when, and under which market’s rules.

Each Market in Its Own Country

Each market is kept in its own country or region, across 24 Microsoft Azure regions, on one MCP server per market. A second copy of every market is made each night on AWS and locked against deletion for 365 days. Allooloo is a Microsoft AI Cloud Partner.

Around the Clock

The products are made around the clock by Allooloo’s own team and AI agents, on the Allooloo Algo. AI agents call them around the clock and pay per call, with no seat and no licence.

“Today we are announcing a milestone: 100M AI agent traffic a month,” said Matthew Keddy, Chief Executive Officer of Allooloo Technologies Corp. “These are the AI agents of capital markets participants, and they want crisp data, five years deep, on 41.9K listed companies across 79 exchanges: sourced, dated and signed. Gain the edge with us.”

In Session and Enterprise Grade

Allooloo is sold two ways. In session, an AI agent calls Allooloo mid-task and pays as it goes (PayGo) on x402, the open payment standard for AI agents, with no seat and no licence. At enterprise grade, a firm licenses the datasets to design, build and run its own AI agents.

About Allooloo Technologies Corp.

Allooloo Technologies Corp. makes agentic capital markets data products for the AI agents of banks, dealers and issuers. Its products, getissuer.ai and Issuerwire.ai, cover 41.9K listed companies on 79 exchanges in 34 countries, kept across 24 Microsoft Azure regions with on-the-fly redundancy on Amazon Web Services (AWS). The result is always-on agentic datasets: in session for AI lab users, and enterprise grade for customers who design, build and run their own AI agents. Allooloo is headquartered in Vancouver, Canada. Please visit: allooloo.ai 

View original content:https://www.prnewswire.com/news-releases/allooloo-tops-100m-capital-markets-ai-agent-traffic-a-month-302947422.html

SOURCE Allooloo Technologies Corp.

Continue Reading

Technology

Allooloo Tops 100M Capital Markets AI Agent Traffic a Month

Published

on

By

Agentic datasets on every listed company in 34 countries: sourced, dated and signed.

VANCOUVER, BC and LONDON, Nov. 21, 2026 /PRNewswire/ — Allooloo Technologies Corp. (Allooloo), maker of agentic datasets for capital markets artificial intelligence (AI) agents, today reported 100M AI agent traffic a month. That is 39 calls a second, 3.4 million a day, across getissuer.ai and Issuerwire.ai, running on 24 Microsoft Azure hyperscale locations globally with always-on Amazon Web Services (AWS) redundancy.

The Data Readiness Gap

Investment banks are not short of AI models. They are short of data an AI agent can use. In a 2026 Teradata study, 77% of technology leaders said 20% or less of their enterprise data is ready for AI agents. Banks are closing that gap on the data they hold, with one governed way in and the source, the date and the owner on every record.

The data a bank does not hold is the other half. An AI agent working on a security needs the issuer, its disclosures and whether it may be ordered, in every market the bank trades. Allooloo delivers that half agent-ready: 41.9K listed companies in 34 countries, a source and a date on every field, and a signed receipt for every read, over Model Context Protocol (MCP).

Two Products

Know Your Product (KYP) is the duty to know a security before it is recommended or sold. Allooloo KYP, at getissuer.ai, answers it for the AI agent: who the issuer is, whether it may be ordered, and who it is for. It covers 41.9K listed companies on 79 exchanges in 34 countries.

Issuerwire.ai is the dated disclosure wire: 3.1 million dated disclosures across 34 countries, each with its source.

Who it matters to:

Investment bank or dealer: its AI agents can show where each fact came from.The issuer: every AI agent reads the same answer about it.Compliance: a signed receipt for every cleared read.

A Signed Receipt for Every Read

Every cleared read on Allooloo leaves a signed receipt, the Record of Cleared Orders (RCO): what was read, when, and under which market’s rules.

Each Market in Its Own Country

Each market is kept in its own country or region, across 24 Microsoft Azure regions, on one MCP server per market. A second copy of every market is made each night on AWS and locked against deletion for 365 days. Allooloo is a Microsoft AI Cloud Partner.

Around the Clock

The products are made around the clock by Allooloo’s own team and AI agents, on the Allooloo Algo. AI agents call them around the clock and pay per call, with no seat and no licence.

“Today we are announcing a milestone: 100M AI agent traffic a month,” said Matthew Keddy, Chief Executive Officer of Allooloo Technologies Corp. “These are the AI agents of capital markets participants, and they want crisp data, five years deep, on 41.9K listed companies across 79 exchanges: sourced, dated and signed. Gain the edge with us.”

In Session and Enterprise Grade

Allooloo is sold two ways. In session, an AI agent calls Allooloo mid-task and pays as it goes (PayGo) on x402, the open payment standard for AI agents, with no seat and no licence. At enterprise grade, a firm licenses the datasets to design, build and run its own AI agents.

About Allooloo Technologies Corp.

Allooloo Technologies Corp. makes agentic capital markets data products for the AI agents of banks, dealers and issuers. Its products, getissuer.ai and Issuerwire.ai, cover 41.9K listed companies on 79 exchanges in 34 countries, kept across 24 Microsoft Azure regions with on-the-fly redundancy on Amazon Web Services (AWS). The result is always-on agentic datasets: in session for AI lab users, and enterprise grade for customers who design, build and run their own AI agents. Allooloo is headquartered in Vancouver, Canada. Please visit: allooloo.ai 

Contact: Matthew Keddy, CEO. mk@allooloo.ai +1 647 237 7744

View original content:https://www.prnewswire.com/apac/news-releases/allooloo-tops-100m-capital-markets-ai-agent-traffic-a-month-302947427.html

SOURCE Allooloo Technologies Corp.

Continue Reading

Technology

Ziehm-Orthoscan Announces Executive Leadership Transition Following 18 Years of Significant Growth

Published

on

By

Ziehm-Orthoscan Announces CEO Transition and Executive Leadership Appointments

SCOTTSDALE, Ariz., Nov. 20, 2026 /PRNewswire-PRWeb/ — Ziehm-Orthoscan Inc., the leader in mobile C-arm imaging solutions, today announced an executive leadership transition as President and Chief Executive Officer Nelson Mendes prepares to step down on December 31, 2026, following 18 years of distinguished leadership.

Effective January 1, 2027, Travis Prikryl will assume the role of Chief Executive Officer, and Hogie Saunders will be appointed Chief Operating Officer. Both executives will also serve as Managing Directors of Ziehm-Orthoscan Inc.

Under Mendes’ leadership, Ziehm-Orthoscan experienced extraordinary growth and transformation, evolving from a small U.S. operation into a major contributor to the company’s global business. Since 2009, U.S. operations have grown from approximately six employees to nearly 200, reflecting Ziehm-Orthoscan’s significant expansion and continued investment. This growth includes the establishment of a new headquarters and production facility in Scottsdale, Arizona, which serves as the global center for the development and manufacturing of all Orthoscan mini C-arm systems.

A significant milestone in this transformation was the acquisition and integration of Orthoscan in 2015, bringing together Ziehm’s full-size mobile C-arm technology and Orthoscan’s mini C-arm expertise. This strategic expansion established a comprehensive mobile imaging portfolio, strengthened the company’s competitive position, and accelerated its growth throughout the U.S. healthcare market.

Throughout his tenure, Mendes championed innovation, operational excellence, and customer relationships, helping establish Ziehm-Orthoscan as a trusted imaging partner to healthcare institutions nationwide.

To ensure a seamless transition, Mendes will remain with the company as a full-time strategic advisor through March 31, 2027, followed by a part-time consulting role supporting the organization’s continued development.

The appointments of Travis Prikryl and Hogie Saunders represent the next chapter in Ziehm-Orthoscan’s long-term growth strategy. Together with the company’s experienced management team, they will focus on advancing imaging innovation, strengthening customer partnerships, expanding market opportunities, and building on the strong foundation established over the past 18 years.

Ziehm-Orthoscan extends its sincere appreciation to Nelson Mendes for his exceptional leadership and contributions while expressing full confidence in the incoming executive team to guide the organization into its next phase of growth and success.

About Ziehm-Orthoscan

Ziehm-Orthoscan is the leader of innovative mobile imaging solutions, combining Ziehm’s expertise in full-size mobile C-arms with Orthoscan’s specialized mini C-arm technology. The company is committed to advancing medical imaging through innovation, exceptional service, and solutions designed to meet the evolving needs of healthcare professionals.

Media Contact

Rich Shaul, Vice President Marketing, Ziehm-Orthoscan, Inc., 1 4805038010, marketing@ziehm-orthoscan.com, https://ziehm-orthoscan.com/

View original content to download multimedia:https://www.prweb.com/releases/ziehm-orthoscan-announces-executive-leadership-transition-following-18-years-of-significant-growth-302946604.html

SOURCE Ziehm-Orthoscan, Inc.

Continue Reading

Trending